Is Ramucirumab a targeted drug?

Ramucirumab, a type of targeted therapy called an angiogenesis inhibitor, is a monoclonal antibody that binds to a protein called VEGFR-2, which works by blocking signals that promote the growth of new blood vessels, which provide oxygen and nutrients for tumor growth.

Ramucirumabcan be combined with other drugs to treat adult patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), and colorectal cancer (mCRC). It can be used as a single drug. For the treatment of patients with hepatocellular carcinoma (HCC), it is administered by intravenous infusion (drip) and is available by prescription only. Treatment should be initiated and supervised by a specialist experienced in cancer treatment. The dosage and frequency of administration depend on the patient's weight and the disease being treated. Treatment should continue as long as the disease is under control and the patient has no unacceptable side effects.

Ramosizumab is usually an injection preparation. The original drug has been on the market in China, but it has been on the market for a short time and has not been included in the medical insurance. The price of 100mg/10mL per box may be around RMB 5,000, and the price of 500mg/50mL per box may be around RMB 17,000. The price of the original Hong Kong version of 100mg/10mL may be around RMB 8,400 per box, and the price of 500mg/50mL per box may be around RMB 28,000 (the price may fluctuate due to exchange rates), and their pharmaceutical ingredients are basically the same. Currently, there are no generic drugs produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.